Alumis ALMS 深 沪
等待开盘 10-10 09:30:00 美东时间
7.16
+0.190
+2.73%
华盛通- 最 高7.285
- 今 开7.04
- 成交量 137.11万股
- 最 低 6.90
- 昨 收 6.97
- 总市值 9.27亿
- 52周最高 31.35
- 市盈率 静 --
- 换手率 1.06%
- 52周最低 4.37
- 委 比 63.72%
- 总股本 1.29亿
- 历史最高 31.35
- 量 比 0.52
- 振 幅 5.52%
- 历史最低 2.7601
- 每 手 1
- 风险率 8.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股周涨跌榜 | 生物医药企业SMMT周涨逾28%！关键药物取得突破；加密货币概念股齐升，IREN周内大涨26%
生物医药企业SMMT周涨逾28%！关键药物取得突破；加密货币概念股齐升，IREN周涨26%！受比特币反弹及云业务双重催化；Strive涨近25%，四天增持约1,800枚比特币>>
09-05 10:16
Alumis to Participate in Upcoming September Investor Conferences
<p>Alumis Inc., a late-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases, announced its participation in four upcoming investor conferences in September 2026. The events include the Wells Fargo Healthcare Conference in Boston, the Cantor Global Healthcare Conference in New York, the Morgan Stanley Global Healthcare Conference in New York, and the Baird Global Healthcare Conference in New York. Each confere...
09-04 12:00
Guggenheim Downgrades Alumis to Neutral
Guggenheim analyst Yatin Suneja downgrades Alumis (NASDAQ:ALMS) from Buy to Neutral.
09-03 21:36
美股大行评级 | 最高735美元！戴尔科技绩后获11家大行上调目标价；MongoDB绩后分歧大，9家上调；4家下调；派拓网络、GitLab、美敦力获多家大行上调目标价
今日重点评级关注：Tigress Financial：维持Liftoff Mobile"买入"评级，目标价从39美元升至41美元；奥本海默：维持SpaceX"跑赢大市"评级，目标价从250美元升至280美元
09-03 13:50
Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37
Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the price target from $55 to $37.
09-03 00:51
BlackRock: Higher rates, selective AI, and unresolved geopolitics define 2026
BlackRock says 2026 has put its long-described new economic regime on full display. As summer ends, the firm is highlighting three lessons investors should carry into the rest of the year: higher inte...
09-02 00:31
Biggest stock movers Tuesday: GPRO, NVS, NIO, and more
Stock futures edged lower on Tuesday, putting Wall Street on track for a weak start to the month as investors weighed escalating Middle East tensions and remained cautious over the outlook for Federal...
09-01 22:23
Alumis Announces Its Phase 2b LUMUS Study Of Envudeucitinib To Treat Lupus Erythematosus Failed To Meet Primary, Secondary Endpoints
Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that its Phase 2b LUMUS trial of envudeucitinib for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) did ...
09-01 19:33
Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate
Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.71) by 56.34 percent. This is a 12.6 percent increase over losses of $(1.27) per share from the same period last year. The company reported quarterly sales of $1.662 million which m...
08-14 04:59
Alumis reports strong Phase 3 data for envudeucitinib
Alumis Inc. ( ($ALMS) ) has issued an announcement. On August 10, 2026, Alumis ...
08-11 06:15
